For its second fiscal quarter (ending June 30), United Therapeutics Corp (NASDAQ: UTHR) has reported E.P.S. of $6.26 compared to $5.53 a year ago. E.P.S. were $23.12 for the latest four quarters through June 30 versus $18.87 for the same period a year ago.
Recent Price Action
On 7/31/24, United Therapeutics Corp (NASDAQ: UTHR) stock suffered a large decline of -7.2%, closing at $313.29. Moreover, this decline was accompanied by unusually high trading volume at 169% of normal. Relative to the market the stock has been exceptionally strong over the last nine months but has declined -7.0% during the last week.
Current PriceTarget Research Rating
UTHR’s future returns on capital are forecasted to exceed the cost of capital. Accordingly, the company is expected to continue to be an important Value Builder.
United Therapeutics has a current Value Trend Rating of A (Highest Rating). The Value Trend Rating reflects highly consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. United Therapeutics has a good Appreciation Score of 74 and a good Power Rating of 79, triggering the Highest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of A. This review will be completed in the next several days.
Be the first to comment